Reports Q3 revenue $2.5B, consensus $2.34B. President and Chief Executive Officer Christopher Viehbacher said: “We delivered another quarter of strong financial performance driven by continued commercial momentum in our launch products, resilience in our MS franchise and our ongoing focus on disciplined cost management. Looking ahead we are further advancing our new Biogen (BIIB) roadmap with a cadence of potentially registrational Phase 3 readouts beginning next year, including data now expected in 2026 from both SLE studies for litifilimab which are fully enrolled. We believe this execution on our strategic objectives, combined with our resilient business model and footprint, positions Biogen to deliver long-term sustainable growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Notable companies reporting before tomorrow’s open
- BIIB Upcoming Earnings Report: What to Expect?
- Biogen’s Strategic Positioning and Promising Pipeline Drive Buy Rating
- Biogen’s PMN Study: A Potential Game-Changer for Kidney Disease Treatment?
- Biogen’s Felzartamab Trial: A New Hope for Kidney Transplant Patients